Drugs that contain Levomilnacipran Hydrochloride
1. List of Fetzima drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8865937 | ALLERGAN | Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide |
May, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE43879 | ALLERGAN | Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug |
Jan, 2026
(2 years from now) | |
| US8481598 | ALLERGAN | Stable dosage forms of levomilnacipran |
Mar, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Oct 7, 2022 |
Market Authorisation Date: 25 July, 2013
Treatment: Treatment of major depressive disorder (mdd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
How can I launch a generic of FETZIMA before it's patent expiration?
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic